The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Research > Signal Research Division

Signal Research Division
 PROFILE
Signal Research Division wants to be the traffic cop for disease. The drug discovery firm, a subsidiary of Celgene, identifies drugs that regulate genes and the production of disease-causing proteins. Signal maps gene-regulating pathways in cells in an effort to identify molecular targets that activate or deactivate genes. The firm hopes to develop treatments that can selectively regulate the activation of these genes. Its drug discovery programs target inflammatory, cardiovascular, and neurological diseases, as well as cancer. Signal works with its parent, as well as with such partners as DuPont, Axys Pharmaceuticals, and Serono.

 COMPETITION
ARIAD Pharmaceuticals, Inc. (ARIA)
Transkaryotic Therapies, Inc. (TKTX)
Vertex Pharmaceuticals Incorporated (VRTX)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 11.70
1-Yr. Sales Growth: (23.8)%
Employees: 87
Revenue per employee: $134,482.76

 KEY PEOPLE
• Alan J. Lewis
    CEO
• Bradley B. Gordon
    CFO

 CONTACT INFO
5555 Oberlin Dr.
San Diego, CA 92121
US
Phone: 858-558-7500
Fax: 858-558-7513
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001